Chronic kidney disease (CKD) substantially increases cardiovascular morbidity, risk of renal failure, and premature mortality. UK guidelines NICE TA775 (2022) recommends dapagliflozin for patients with CKD (eGFR 25-75 mL/min/1.73m²) on optimised ACEi/ARB therapy who also have type 2 diabetes or significant albuminuria (ACR ≥22.6 mg/mmol). Large clinical trials have demonstrated the reno- and cardioprotective benefits of SGLT2-inhibitors, yet real-world uptake in CKD patients remains suboptimal, particularly in primary care where most CKD is managed.To evaluate SGLT2-inhibitor implementation in primary care by identifying CKD patients eligible for dapagliflozin and examining renal monitoring patterns.A retrospective cross-sectional analysis was conducted in a UK general practice setting using electronic health records (April 2025). Adults (≥18 years) previously recorded as CKD G3a-G5 were included. Exclusion criteria were type 1 diabetes and current SGLT2-inhibitor use.Of 158 patients with CKD 3a-5, 38 (24.1%) met general TA775 criteria. After exclusions (n=25), 13 patients (8.2%) remained eligible for dapagliflozin. Additionally, 32 patients (20.3%) were overdue for renal testing, including 15 patients (9.5%) with no ACR result on record. These findings indicate gaps in essential testing and prescribing processes needed to identify and treat eligible patients.Suboptimal ACR testing, incomplete ACEi/ARB optimisation and variability in clinician familiarity with updated CKD guidance likely contributed to low eligibility recognition. These results reflect national data: the 2017 National CKD Audit (NCKDA) reported proteinuria measurement in <15% of non diabetic and 54% of diabetic patients. Global KDIGO guidelines align closely with UK guidelines on dapagliflozin prescription, demonstrating the growing importance of addressing this implementation gap.This study identifies a substantial mismatch between NICE TA775 guidance and real-world CKD management. System-level interventions such as electronic alerts, strengthened eGFR/ACR recall systems, and structured medication reviews may improve uptake of dapagliflozin and overall CKD care quality. Given the international approval of SGLT2-inhibitors for CKD, implementation gaps identified here may highlight opportunities for stronger CKD management globally.